The European Medicines Agency (EMA) has made a decision regarding the case-by-case use of a medicine.
1 report, 1 independent
Updated Jun 11
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
The European Medicines Agency (EMA) has made a decision regarding the case-by-case use of a medicine.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.- The European Medicines Agency (EMA) is evaluating experimental treatments that were developed in Japan.Sub-event
EMA decided on the case-by-case use of medicine.1 source
Keep exploring
The entities involved
-
European Medicines Agency
highest regulatory authority on medicines in the European Union
- Japan
Related events
- EMA adopted a positive opinion for Sobi's drug, with the European Commission set to confirm the decision.
- Glenn attended a congress in Amsterdam and participated in a panel with an official from the European Medicines Agency.
- Both the FDA and the European Medicines Agency govern drug approval processes.
- Omeros Corporation's drug received FDA approval and is currently undergoing review by the European Medicines Agency.